Werewolf Therapeutics, Inc.
HOWL
$0.71
$0.0568.56%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -1.17% | -17.96% | |||
| Gross Profit | 1.17% | 11.33% | |||
| SG&A Expenses | 73.35% | -4.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.83% | -14.82% | |||
| Operating Income | -18.83% | 9.68% | |||
| Income Before Tax | -22.35% | 3.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.35% | 3.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.35% | 3.34% | |||
| EBIT | -18.83% | 9.68% | |||
| EBITDA | -19.41% | 9.92% | |||
| EPS Basic | -20.24% | 3.73% | |||
| Normalized Basic EPS | -20.26% | 0.58% | |||
| EPS Diluted | -20.24% | 10.32% | |||
| Normalized Diluted EPS | -20.26% | -0.63% | |||
| Average Basic Shares Outstanding | 1.77% | 0.42% | |||
| Average Diluted Shares Outstanding | 1.77% | -0.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
